US Primary Cells Market

ID: MRFR/LS/17960-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Primary Cells Market Research Report: Size, Share, Trend Analysis By Source (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, Skeletal and Muscle Cells), By Types (Human Primary Cells, Animal Primary Cells) and By End Users (Pharmaceutical and Biotechnology Companies, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Primary Cells Market Infographic
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Source (USD Million)
      1. 4.1.1 Hematopoietic Cells
      2. 4.1.2 Skin Cells
      3. 4.1.3 Gastrointestinal Cells
      4. 4.1.4 Liver Cells
      5. 4.1.5 Lung Cells
      6. 4.1.6 Skeletal and Muscle Cells
    2. 4.2 Pharmaceutical, BY Type (USD Million)
      1. 4.2.1 Human Primary Cells
      2. 4.2.2 Animal Primary Cells
    3. 4.3 Pharmaceutical, BY End User (USD Million)
      1. 4.3.1 Pharmaceutical and Biotechnology Companies
      2. 4.3.2 Research Institutes
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck KGaA (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Lonza Group (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Corning Incorporated (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Becton Dickinson and Company (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Promega Corporation (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 F. Hoffmann-La Roche Ltd (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sigma-Aldrich (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY SOURCE
    3. 6.3 US MARKET ANALYSIS BY TYPE
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 KEY BUYING CRITERIA OF PHARMACEUTICAL
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF PHARMACEUTICAL
    8. 6.8 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    11. 6.11 PHARMACEUTICAL, BY SOURCE, 2024 (% SHARE)
    12. 6.12 PHARMACEUTICAL, BY SOURCE, 2024 TO 2035 (USD Million)
    13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
    14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
    16. 6.16 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY SOURCE, 2025-2035 (USD Million)
      2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Source (USD Million, 2025-2035)

  • Hematopoietic Cells
  • Skin Cells
  • Gastrointestinal Cells
  • Liver Cells
  • Lung Cells
  • Skeletal and Muscle Cells

Pharmaceutical By Type (USD Million, 2025-2035)

  • Human Primary Cells
  • Animal Primary Cells

Pharmaceutical By End User (USD Million, 2025-2035)

  • Pharmaceutical and Biotechnology Companies
  • Research Institutes

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035